S&P Biotech ETF (CURE) – Global X ETFs Australia

CURE


S&P Biotech ETF

Reasons to Consider CURE

High Growth Potential

Genomic sequencing and genetic medicines & therapeutics are helping transform health care in key areas with growing demand, including drug development, precision medicine, and more.

Risk Controls

Limit company-specific risks, such as risk of testing failures or higher than anticipated development costs, by using an equal weighting across many biotechnology companies.

Targeted Exposure

CURE provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.

Product Information As of 11 Jun 2024

Inception Date 8 Nov 2018
Management Costs (% p.a.) 0.45
Currency Hedged No
Domicile Australia
Legal Form Managed Investment Scheme
SMSF Eligible Yes

NAV Information As of 11 Jun 2024

NAV/Unit (A$) 47.83150000
Currency (NAV) AUD
Shares Outstanding 824,012
AUM (A$) 39,413,769.92
NAV History File View

Product Summary

The Global X S&P Biotech ETF (CURE) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

Product Objective

The Global X S&P Biotech ETF (CURE) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the S&P Biotechnology Select Industry Index.

Trading Details

Ticker CURE
Bloomberg Code CURE AU Equity
ISIN AU0000028110
Trading Hours 10:00AM – 4:00PM

Management & Administration

Issuer Global X Management (AUS) Limited
Custodian The Hongkong and Shanghai Banking Corporation Limited, Sydney Branch
Registrar Computershare Investor Services Pty Limited

Benchmark Information

Benchmark S&P Biotechnology Select Industry Index
Provider S&P Indices
Ticker SPSIBIN

Distributions As of 31 May 2024

12-Month Yield 0.00%
12-Month Franking Level 0.00%
Distribution Frequency Annually
Distribution History View

Performance Table As of 11 Jun 2024

Total Return (Fund) Total Return (Benchmark) Tracking Difference Tracking Error
1 Month 0.43% 0.46% -0.04% 0.04%
3 Months -11.38% -11.29% -0.09% 0.36%
1 Year 4.53% 5.35% -0.82% 0.54%
3 Year p.a. -5.94% -5.64% -0.30% 1.00%
5 Year p.a. 2.68% 3.09% -0.42% 0.86%
10 Year p.a. -- -- -- --
Since Inception p.a. 2.84% 3.27% -0.43% 0.84%

Top Holdings As of 12 Jun 2024

Net Assets (%) Name SEDOL Market Price (Local) Shares Held Market Value (A$)
3.28 NOVAVAX INC BJDQXG4 16.73 50,951 1,292,026
2.38 INSMED INC 2614487 61.87 9,981 936,282
1.54 MODERNA INC BGSXTS3 148.39 2,695 606,339
1.47 TWIST BIOSCIENCE BGKG6G7 51.59 7,391 578,124
1.43 GERON CORP 2370381 5.09 73,011 563,454
1.35 NATERA INC BYQRG48 112.47 3,118 531,698
1.29 REVOLUTION MEDIC BL71K91 39.02 8,610 509,381
1.29 PTC THERAPEUTICS B17VCN9 37.69 8,912 509,276
1.28 HALOZYME THERAPE 2975098 49.92 6,654 503,628
1.24 VERTEX PHARM 2931034 481.53 671 489,890
1.24 DYNE THERAPEUTIC BN15WD1 30.96 10,428 489,502
1.22 AGIOS PHARMACEUT BCBVTX1 47.51 6,698 482,483
1.22 MADRIGAL PHARMAC BD59BS7 291.99 1,088 481,670
1.22 BLUEPRINT MEDICI BWY52P3 105.40 3,008 480,673
1.21 UNITED THERAPEUT 2430412 275.76 1,142 477,474
1.18 BIOCRYST PHARM 2100362 6.48 47,533 467,006
1.17 AMGEN INC 2023607 300.70 1,014 462,300
1.13 CRINETICS PHARMA BDD19F8 44.82 6,566 446,195
1.12 REGENERON PHARM 2730190 1,010.54 287 439,732
1.12 ALNYLAM PHARMACE B00FWN1 156.43 1,853 439,489
1.10 KRYSTAL BIOTECH BD6JX35 177.48 1,616 434,854
1.09 DENALI THERAPEUT BD2B4V0 21.60 13,169 431,280
1.08 BIOGEN INC 2455965 225.74 1,244 425,776
1.07 VAXCYTE INC BKPVGH6 72.58 3,820 420,371
1.06 EXELIXIS INC 2576941 22.03 12,503 417,620
1.06 INCYTE CORP 2471950 59.48 4,626 417,185
1.06 ROIVANT SCIENCES BMW4NZ9 10.57 26,000 416,678
1.04 CEREVEL THERAPEU BMVMJ12 40.28 6,732 411,136
1.04 SAREPTA THERAPEU B8DPDT7 121.38 2,233 410,949
1.04 BIOMARIN PHARMAC 2437071 83.87 3,231 410,862
1.03 TG THERAPEUTICS B828K63 16.15 16,548 405,201
1.02 RHYTHM PHARMACEU BF2YWG4 40.12 6,621 402,751
1.02 NEUROCRINE BIOSC 2623911 133.15 1,995 402,751
1.01 BRIDGEBIO PHARMA BK1KWG8 27.48 9,582 399,232
1.00 ABBVIE INC B92SR70 167.70 1,553 394,872
1.00 NUVALENT INC-A BMVBZD3 79.05 3,290 394,321
0.98 DYNAVAX TECHNOLO BRJZSK0 12.09 21,133 387,382
0.96 IONIS PHARMACEUT BDJ0LS6 39.69 6,312 379,840
0.95 PROTAGONIST THER BDCBCD8 33.95 7,243 372,830
0.92 GILEAD SCIENCES 2369174 64.89 3,697 363,730
0.91 IMMUNITYBIO INC BNSP0B8 5.96 39,678 358,549
0.91 ALKERMES PLC B3P6D26 24.79 9,493 356,806
0.90 AMICUS THERAPEUT B19FQ48 10.40 22,576 355,986
0.88 CATALYST PHARMAC B1G7Q03 15.56 14,739 347,720
0.88 IDEAYA BIOSCIENC BK0VHF6 37.58 6,095 347,282
0.88 ROCKET PHARMACEU BDFKQ07 22.91 9,963 346,073
0.88 ULTRAGENYX PHARM BJ62Z18 41.40 5,495 344,922
0.87 VERICEL CORP BSBMN89 43.31 5,219 342,711
0.87 CYTOKINETICS INC BBBSBJ5 53.29 4,223 341,208
0.85 KYMERA THERAPEUT BMPRZV5 34.57 6,385 334,667
0.85 INTELLIA THERAPE BYZM6C2 23.75 9,265 333,627
0.85 IMMUNOVANT INC BJRFSB7 25.10 8,762 333,449
0.84 CRISPR THERAPEUT BDHF4K6 62.31 3,519 332,452
0.84 SYNDAX PHARMACEU BN7Q7R7 19.32 11,302 331,066
0.83 ADMA BIOLOGICS I B9NSBM2 10.50 20,659 328,890
0.82 RECURSION PHAR-A BM9FJ13 8.58 24,815 322,815
0.81 ARDELYX INC BN89V40 6.63 31,954 321,211
0.81 SPRINGWORKS THER BGMGM89 38.92 5,437 320,837
0.81 MIRUM PHARMACEUT BJDX8Y8 26.20 8,063 320,295
0.80 ARCELLX INC BPCJ1Q2 54.00 3,838 314,232
0.80 AKERO THERAPEUTI BK7Y2V9 23.43 8,827 313,572
0.79 CELLDEX THERAPEU BJLV8T9 35.57 5,796 312,582
0.79 ARROWHEAD PHARMA BYQBFJ8 24.64 8,301 310,115
0.78 VIKING THERAPEUT BQQG1V1 52.73 3,869 309,321
0.78 VERA THERAPEUTIC BL55460 38.43 5,293 308,407
0.78 KURA ONCOLOGY IN BYZD465 21.49 9,425 307,093
0.77 VERACYTE INC BFTWZY0 21.29 9,343 301,588
0.75 EXACT SCIENCES 2719951 42.14 4,625 295,501
0.75 ARCUTIS BIOTHERA BKX9VD3 7.78 24,904 293,766
0.74 IRONWOOD PHARMAC B3MZ6K5 6.25 30,819 292,046
0.73 APELLIS PHARMACE BYTQ6X1 42.75 4,466 289,472
0.73 MORPHIC HOLDING BK8M4J4 28.20 6,685 285,827
0.72 PROTHENA CORP PL B91XRN2 20.49 9,189 285,471
0.72 COGENT BIOSCIENC BLR6XK8 8.82 21,154 282,887
0.70 BEAM THERAPEUTIC BK6L288 24.86 7,333 276,398
0.68 ACADIA PHARMACEU 2713317 15.03 11,742 267,580
0.67 AVIDITY BIOSCIEN BMWHPY1 28.92 6,032 264,492
0.67 REPLIMUNE GROUP BDDVW37 9.00 19,270 262,952
0.67 ALTIMMUNE INC BFY7DC4 6.48 26,726 262,580
0.66 KEROS THERAPEUTI BM7V485 47.87 3,587 260,344
0.65 MYRIAD GENETICS 2614153 22.47 7,479 254,800
0.64 DECIPHERA PHARMA BZ1LFB2 25.59 6,550 254,135
0.64 VIRIDIAN THERAPE BMDH2B6 13.46 12,272 250,445
0.63 CAREDX INC BP3YM74 14.89 10,948 247,162
0.62 BIOHAVEN LTD BPLZ7S5 34.21 4,748 246,273
0.61 ARCUS BIOSCIENCE BDZT9Y9 15.65 10,194 241,886
0.59 ARCTURUS THERAPE BKC9SX3 32.36 4,742 232,660
0.58 IOVANCE BIOTHERA BF0DMK7 8.62 17,530 229,109
0.58 XENCOR INC BGCYWN8 21.94 6,884 228,997
0.57 SOLENO THERAPEUT BL6JK96 46.43 3,186 224,283
0.57 SUMMIT THERAPEUT BMTVQS7 7.54 19,516 223,108
0.54 VIR BIOTECHNOLOG BK4PZ38 10.63 13,185 212,403
0.51 EDITAS MEDICINE BZ8FPH3 5.43 24,186 199,121
0.49 TRAVERE THERAPEU BLFGJD5 7.07 17,864 191,492
0.48 AVID BIOSERVICES BFMZ4W7 7.99 15,774 191,091
0.48 SAGE THERAPEUTIC BP4GNK9 10.60 11,777 189,275
0.47 C4 THERAPEUTICS BKX9NQ0 4.86 25,020 184,364
0.46 DISC MEDICINE IN BMGJZJ8 39.13 3,087 183,147
0.46 OLEMA PHARMACEUT BMZ4LN0 13.62 8,845 182,653
0.46 89BIO INC BK1K484 8.68 13,864 182,457
0.45 CABALETTA BIO IN BK5MWR1 11.07 10,637 178,533
0.42 4D MOLECULAR THE BKLXFX5 23.29 4,669 164,872
0.39 SANA BIOTECHNOLO BMFJJ97 6.89 14,884 155,486
0.39 NURIX THERAPEUTI BMVLGP2 16.15 6,345 155,366
0.39 MANNKIND CORP BF081J4 4.65 21,972 154,908
0.39 RELAY THERAPEUTI BN2R582 7.23 13,928 152,679
0.39 SCHOLAR ROCK HOL BFZQ0L8 9.70 10,377 152,615
0.34 ZENTALIS PHARMAC BMQ5T49 9.99 8,944 135,472
0.33 APOGEE THERAPEUT BM9HHL5 43.21 1,985 130,046
0.33 FATE THERAPEUTIC BCZS820 3.89 21,898 129,154
0.31 KINIKSA PHARMA-A BD0MGM0 18.76 4,228 120,260
0.29 ANAVEX LIFE SCIE BYTYP72 3.70 20,107 112,798
0.28 REGENXBIO INC BZ0G875 13.58 5,398 111,144
0.28 DAY ONE BIOPHARM BLB0YH0 12.54 5,799 110,256
0.27 VERVE THERAPEUTI BNKGXX2 5.33 12,952 104,669
0.26 CULLINAN THERAPE BM90J52 23.25 2,913 102,687
0.25 ANAPTYSBIO INC BDRW1L7 23.65 2,722 97,605
0.24 BIOMEA FUSION IN BNKF6N0 4.43 14,357 96,432
0.23 MIMEDX GROUP INC B1Z3TW5 6.98 8,651 91,553
0.23 ALLOGENE THERAPE BFZNYB7 2.55 23,582 91,174
0.20 MACROGENICS INC BFDV8K0 4.93 10,585 79,121
0.18 TANGO THERAPEUTI BP2P6L0 6.92 6,603 69,279
0.16 ASTRIA THERAPEUT BMYRFN8 9.08 4,698 64,677
0.14 ALECTOR INC BJ4LDC4 4.42 8,272 55,435
0.12 CARIBOU BIOSCIEN BNYJR68 1.94 16,250 47,798
0.12 VOYAGER THERAPEU BY7RB53 8.67 3,578 47,034
0.12 ARS PHARMACEUTIC BMCR7V2 8.97 3,348 45,533
0.11 SCILEX HOLDING C BLKFRT9 1.33 21,910 44,182
0.10 ORIC PHARMACEUTI BKVDFF7 8.01 3,336 40,515
0.10 INHIBRX BI BNSP8K3 16.84 1,515 38,682
0.10 MERSANA THERAPEU BF3NP05 2.26 11,057 37,888
0.10 CARGO THERAPEUTI BQHN2F2 17.42 1,428 37,716
0.05 AVITA MEDICAL IN BMX0JN6 8.99 1,549 21,114
Holdings are subject to change.

Sector Breakdown As of 12 Jun 2024

Sector Weight (%)
Health Care 99.8
Other/Cash 0.2

Country Breakdown As of 12 Jun 2024

Country Weight (%)
United States 97.3
Ireland 1.6
Switzerland 0.8
Other/Cash 0.3

Research

FAQs

  • What is biotechnology?

    Biotechnology includes companies primarily engaged in the research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering. It includes companies specialising in protein-based therapeutics to treat human diseases. It excludes companies manufacturing products using biotechnology but without a healthcare application. Biotechnology is a sub-industry of the healthcare sector.
  • How does biotechnology differ from healthcare?

    Biotechnology is a sub-industry within the Healthcare sector.

    The Healthcare sector refers to all those industries involved in providing goods and services to manage the health needs of individuals and populations. There are two main groupings within the healthcare sector according to the Global Industry Classification Standards (GICS) including:

    Healthcare equipment and services

    Pharmaceuticals, biotechnology, and Life Sciences.
  • How are companies in CURE weighted?

    Companies in CURE are equally weighted (subject to liquidity constraints), meaning each holding makes up the same portion of the portfolio at each quarterly rebalance and therefore contributes equally to overall performance.

    The choice of an equal weighting scheme provides investors exposure to the overall sector and allows all stocks to contribute equally to returns. Large-cap stocks do not dominate as they do where holdings are weighted by market capitalisation.
  • Why use CURE for biotechnology exposure?

    While biotechnology can be a lucrative space, it can also be high risk. The drug development process is very lengthy with high failure rates and it is an area that is sensitive to government policy. Using an ETF like CURE not only spreads the risk over many biotechnology companies but reduces the single stock risk further by using an equal weight method.

    CURE enables investors to access the growth in the U.S. biotechnology sector, without having to pick individual winners.
  • How can you use CURE in a portfolio?

    CURE may be used as a tool for expressing long-term strategic or short-term tactical views on the biotechnology sub-industry.

    CURE can also aid portfolio diversification via investment in a sector that is underrepresented in the Australian market.

Global X Management (AUS) Limited (“Global X”) (Australian Financial Services Licence Number 466778, ACN 150 433 828) is the product issuer. Offers of interests in any retail product will only be made in, or accompanied by, a Product Disclosure Statement (PDS). In respect of each retail product, Global X has prepared a target market determination (TMD). Each PDS and TMD is available at www.globalxetfs.com.au. The information on this website is general in nature only and does not take into account your personal objectives, financial situations or needs. Before acting on any information, you should consider the appropriateness of the information having regard to your objectives, financial situation or needs and consider seeking independent financial, legal, tax and other relevant advice having regard to your particular circumstances. Any investment decision should only be made after obtaining and considering the relevant PDS and TMD. Investments in any product issued by Global X are subject to investment risk, including possible delays in repayment and loss of income and principal invested. The value or return of an investment will fluctuate and an investor may lose some or all of their investment. Past performance is not a reliable indicator of future performance.

Back to Top
git